

# The clinical significance of sCD14-ST for blood biomarker in neonatal hematosepsis

## A diagnostic accuracy study

Ting Xiao, Master's Degree<sup>a</sup>, Li-Ping Chen, Master's Degree<sup>a</sup>, Li-hua Zhang, Bachelor's Degree<sup>b</sup>, Fu-Huang Lai, Bachelor's Degree<sup>b</sup>, Li Zhang, Bachelor's Degree<sup>b</sup>, Qun-feng Qiu, Bachelor's Degree<sup>a</sup>, Rong-Liang Que, Bachelor's Degree<sup>a</sup>, SiSi Xie, Master's Degree<sup>a</sup>, Ding-Chang Wu, Bachelor's Degree<sup>a,\*</sup>

### Abstract

Hematosepsis is a systemic inflammatory response syndrome (SIRS) with suspected or confirmed infection, which is the most common infectious disease in clinical neonatal intensive care unit. As the rapid development of neonatal hematosepsis caused by various basic diseases, the mortality rate is high, and there are some sequelae.

We report the lasted study to date with 96 cases from Fujian Longyan First Hospital between 2013 and 2015. The aim of our study is to explore the value of soluble cluster of differentiation 14 subtype (sCD14-ST) in whole blood for differential diagnosis of neonatal hematosepsis at an early stage, and used in evaluation of the severity about sepsis combined with acute physiology and chronic health evaluation II (APACHE-II) score, procalcitonin (PCT), C reactive protein (CRP), and leukocyte (WBC).

In our cohort, all cases met the diagnostic criteria for hematosepsis specific for newborns. We selected 42 neonates with hematosepsis, 54 neonates with nonhematosepsis, 44 noninfectious SIRS neonates, and 53 healthy neonatal controls. Which were determined the sCD14-ST, PCT, CRP, and WBC of all samples before treatment. Then assign the APACHE-II score for the all samples before and after treatment.

The study shows, sCD14-ST levels were significantly higher in hematosepsis than nonhematosepsis group ( $t = -2.112, P = .041$ ). Meanwhile, sCD14-ST levels were significantly higher in neonatal hematosepsis than in noninfectious SIRS group and controls ( $\chi^2 = 57.812, 68.944, P < .01$ ). However, sCD14-ST in hematosepsis group was positively correlated with APACHE-II score ( $R$ -value = 0.415,  $P < .01$ ). During treatment, the sCD14-ST level was decreased obviously along with APACHE-II score, PCT, CRP, and WBC ( $\chi^2 = 35.019, 78.399, 52.363, 25.912, 7.252$ , all  $P$  values  $< .01$ ). The area under the curve (AUC) of sCD14-ST was 0.942. The differences in ROC<sup>AUC</sup> of sCD14-ST compared with PCT, CRP, and WBC were statistically significant ( $Z = -6.034, -4.474, -5.722$ , all  $P$  values  $< .01$ ). The sensitivity and specificity of sCD14-ST were 95.2% and 84.9%, respectively.

sCD14-ST could be a blood biomarker for early identification and disease valuation in newborns hematosepsis infection; and its diagnostic value is superior to other laboratory indexes.

**Abbreviations:** APACHE = acute physiology and chronic health evaluation, AUC = area under curve, CRP = C reactive protein, G<sup>-</sup> = gram-negative bacteria, G<sup>+</sup> = gram-positive bacteria, PCT = procalcitonin, PICU = pediatric intensive care unit, ROC = receiver operating characteristic curve, sCD14-ST = soluble cluster of differentiation 14 subtype, SIRS = systemic inflammatory response syndrome, WBC = leukocyte.

**Keywords:** gram-negative bacteria, gram-positive bacteria, hematosepsis, neonate, sCD14-ST

Editor: Yuxuan Liu.

Funding: The youth research funding project of health department in Fujian Province (2013-2-149, 2016-1-96).

The authors have no conflicts of interest to disclose.

<sup>a</sup> Department of Clinical Laboratory, <sup>b</sup> Department of Neonatal Unit, Fujian Longyan First Hospital, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, Fujian, China.

\* Correspondence: Ding-Chang Wu, Department of Clinical Laboratory, Fujian Longyan First Hospital, Longyan First Affiliated Hospital of Fujian Medical University, No. 105 North Jiu Yi Road, Longyan 364000, Fujian, China (e-mail: wudcly@163.com).

Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Medicine (2017) 96:18(e6823)

Received: 27 December 2016 / Received in final form: 23 March 2017 /

Accepted: 13 April 2017

<http://dx.doi.org/10.1097/MD.0000000000006823>

## 1. Introduction

Systemic inflammatory response syndrome (SIRS) triggered by infectious causes will be resulted in hematosepsis.<sup>[1]</sup> The source of infection can be placental abruption at birth, mother-to-fetus transmission, living environment, hospital infection, etc. A number of pathogenic bacteria may invade blood circulation, then release and disseminate toxins by reproduction. It will be terrible if we only treat with amount of broad-spectrum antibiotic as normal infection.<sup>[2]</sup>

Hematosepsis will appear and develop rapidly, and may result in systemic multiple organ failure; the mortality of hematosepsis is extremely high and about 30% to 50% neonatal deaths annually.<sup>[3]</sup> In premature, hematosepsis could affect various system growth seriously and cause various abdominal organs disease.<sup>[4,5]</sup> With the improvement of medical technology, the researchers have found more than one hundred laboratory markers applied to clinic.<sup>[6]</sup> Although, blood culture is still the "gold standard" for diagnosis of hematosepsis, which can be used to identify the type of bacteria in a timely and accurate

manner, providing a reliable basis for rational clinical practice of antibacterial drugs. However, such identification takes much time and is susceptible to contamination and antibiotic. The laboratory indexes of hematosepsis have been researched for many years.

As a marker rarely reported, soluble cluster of differentiation 14 subtype (sCD14-ST) is one of the main receptors of lipopolysaccharide (LPS) and the fragment of leukocyte differentiation antigen CD14, including soluble CD14 (sCD14) and membrane CD14 (mCD14).<sup>[12,15]</sup> Application of sCD14-ST in judgment of severity and prognosis of neonatal hematosepsis is still absent. In this study, the type of bacteria was identified through the detection of sCD14-ST level in whole blood of the neonate with hematosepsis; meanwhile, comparison of area under curve (AUC) was made among sCD14-ST, procalcitonin (PCT), leukocyte (WBC), and C reactive protein (CRP), respectively; the value of sCD14-ST for diagnosis and severity assessment of neonatal hematosepsis at an early stage was evaluated.

## 2. Patients and methods

### 2.1. Our case series

The neonates visited the pediatric intensive care unit (PICU) of Fujian Longyan First Hospital, China, from August 2013 and March 2015. Data were collected by a single author in 96 neonates with infectious SIRS (including 42 hematosepsis, and 54 nonhematosepsis), there were 50 males (52.1%) and 46 females (47.9%), whose gestational age was  $37.9 \pm 2.55$  weeks on average. These neonates included 79 full-term infants and 17 premature infants (28 weeks < gestational age < 37 weeks), with mean birth weight of  $3008.33 \pm 596.64$  g. Cases with congenital diseases or recently treated with immunosuppressant, and treated for more than 3 days in other hospitals were excluded. All cases in the study met the diagnostic criteria for hematosepsis specific for children (including newborns) established by international pediatric experts based on the physiological features of children at different ages in 2005.<sup>[7]</sup> Fifty-three health controls included 28 males (28/53, 52.83%) and 25 females (25/53, 47.16%), with average gestational age of  $38.77 \pm 1.41$  weeks and birth weight of

$3238.25 \pm 545.72$  g. Cases with mal-development or congenital diseases were excluded. Details are shown in Table 1.

### 2.2. Methods

**2.2.1. Sample collection.** All subjects were collected of 2 mL venous blood in EDTA anticoagulant tubes and 5 mL venous blood in separation gel tubes.

**2.2.2. Reagents and instruments.** sCD14-ST, PCT, CRP, and WBC were determined by PATHFAST Immunoanalyzer and Reagents (fluorescent enzyme immunoassay, Mitsubishi Chemical Medience Corporation, Tokyo, Japan), Immunochematometer Reader HR 201 (Immuno-chromatographic assay, B.R.A.H.M.S. GmbH, Germany), Olympus AU2700 Automated Chemistry Analyzer (Immune scatter turbidimetry, Beckman Coulter, Inc., Osaka, Japan), and Sysmex XE-5000 Automated Hematology Analyzer (Electrical impedance method and optical method, SYSMEX Corporation, Kobe, Japan), respectively. BD BACTEC FX Instrument and BD Phoenix-100 (New York) were used for blood culture and bacteria identification. Blood culture bottles and bacteria identification panels were purchased from Becton, Dickinson and Company (New York).

Collection and processing of clinical data: The name, gender, age, medical history, and blood biochemical test results of patients were recorded. Acute physiology and chronic health evaluation II (APACHE-II) scores were obtained for hematosepsis group.<sup>[8,9]</sup> Blood specimens were taken from neonates with hematosepsis and then cultured in bacteriology room. True or false-positive results were determined in combination with clinical symptoms. This study was approved by the Ethics Committee of Longyan First Affiliated Hospital of Fujian Medical University, Longyan, China. Written informed parental consent was obtained for all patients.


### 2.3. Statistical analysis

SPSS 19.0 statistical software was used, and normality test was done for all data. Measurement data were expressed in median (quartile) [M ( $P_{25}$ - $P_{75}$ )] or mean  $\pm$  SD ( $\pm$ s). Kruskal-Wallis *H* test was used for 3-group comparison, and paired *t* test was used

**Table 1**

**Basic data composition of neonates.**

	Hematosepsis group	Nonhematosepsis group	Noninfectious group	Healthy control group
Cases	42	54	44	53
Gender				
Male	21 (50.0%)	30 (55.6%)	23 (52.27%)	28 (52.83%)
Female	21 (50.0%)	24 (44.4%)	21 (47.72%)	25 (47.16%)
Gestational age	42/37.85 $\pm$ 2.44	54/37.91 $\pm$ 2.55	44/38.75 $\pm$ 1.98	38.77 $\pm$ 1.41
Preterm birth (28–37 wk)	7/33.41 $\pm$ 2.47 (16.7%)	7/32.65 $\pm$ 3.65 (13.0%)	2/32.73 $\pm$ 1.27 (4.5%)	—
Term $\geq$ 37 wk	35/38.74 $\pm$ 1.10 (83.3%)	47/38.69 $\pm$ 1.14 (87.0%)	42/39.19 $\pm$ 1.11 (95.5%)	53/38.84 $\pm$ 1.76
Birth weight, g	42/2949.76 $\pm$ 638.99	54/3053.88 $\pm$ 563.36	44/3316.25 $\pm$ 753.06	53/3093.77 $\pm$ 585.97
<1500	—	1/1480 (1.8%)	2/1370.00 $\pm$ 155.56 (4.5%)	1/1360 (1.9%)
<2000	5/1836.00 $\pm$ 166.52 (11.9%)	3/1815.00 $\pm$ 21.21 (5.6%)	—	1/1620 (1.9%)
<2500	4/2245.00 $\pm$ 121.91 (9.5%)	5/2176.00 $\pm$ 91.11 (9.3%)	1/2490 (2.3%)	5/2340.00 $\pm$ 151.65 (9.4%)
$\geq$ 2500	33/3209.93 $\pm$ 442.45 (78.6%)	45/3237.39 $\pm$ 360.06 (83.3%)	41/3431.34 $\pm$ 623.69 (93.1%)	46/3245.43 $\pm$ 438.73 (86.8%)
Nature of childbirth				
Eutocia	25 (59.5%)	30 (55.6%)	30 (68.2%)	37 (69.8%)
Cesarean	17 (40.5%)	24 (44.4%)	14 (31.8%)	16 (30.2%)
Agar score				
4–7 points	2 (4.8%)	—	—	—
8–10 points	40/9.32 $\pm$ 0.85 (95.5%)	54/9.77 $\pm$ 0.54 (100.0%)	9.93 $\pm$ 0.25	9.94 $\pm$ 0.23



**Figure 1.** Comparison of sCD14-ST levels (ng/L) among hematosepsis group and nonhematosepsis group, noninfectious group and healthy control group.

for pairwise comparison. Receiver operating characteristic curve (ROC) analysis was performed on data,<sup>[10]</sup> and the AUC of 1.0 suggests optimal test index, AUC of a diagnostic test without any significance is 0.5. In general, a diagnostic test is of low value when its ROC-AUC is between 0.5 and 0.7, of medium value when its ROC-AUC is between 0.7 and 0.9, and of great value when its ROC-AUC is higher than 0.9.  $P < .01$  indicated significant statistical difference. Pearson test was used for correlation analysis.

### 3. Results


#### 3.1. Basic data of neonates (Table 1)

Significant differences in sCD14-ST levels were observed among hematosepsis group and nonhematosepsis group, noninfectious group and healthy control group (all  $P$  values  $< .01$ ), seen in Fig. 1.

Comparison of all laboratory indexes before treatment between hematosepsis and nonhematosepsis group showed that there was significant difference in sCD14-ST levels of 2 groups ( $P < .05$ ), but not in PCT, CRP, and WBC ( $P > .05$ ), seen in Table 2.

The correlation of sCD14-ST with APACHE-II score obtained from neonates in hematosepsis group before treatment showed that sCD14-ST had significantly positive correlation with APACHE-II score in hematosepsis group ( $R = 0.415$ ,  $P < .01$ ), seen in Fig. 2.

ROC curve analysis of sCD14-ST, WBC, CRP, and PCT for 42 neonates with hematosepsis ROC curves are shown in Fig. 3.



**Figure 2.** Correlation analysis of sCD14-ST with APACHE-II score in hematosepsis group.

Evaluation of diagnostic capabilities of sCD14-ST, WBC, CRP, and PCT is seen in Table 3. Differences in  $AUC^{ROC}$ , sensitivity and specificity among 4 indexes were statistically significant ( $P < .01$ ).

Results showed that sCD14-ST, PCT, WBC, CRP, and APACHE-II score obtained from 42 neonates with hematosepsis were all apparently decreased before and after treatment ( $P < .01$ ), seen in Table 4.

In 42 neonates with hematosepsis, sCD14-ST in gram-positive bacteria and gram-negative bacteria group were both higher than those in healthy control group ( $P < .01$ ), but sCD14-ST between gram-positive bacteria and gram-negative bacteria group was not statistically different ( $P > .05$ ), results seen in Table 5.

After blood culture in 42 cases of neonatal hematosepsis, gram-positive cocci were found to be in the majority, accounting for 60% (25/42), followed by gram-negative bacilli, accounting for 40% (17/42), results seen in Table 6. And there is 17 cases of neonatal hematosepsis were premature infant, the bacteria were mainly gram-negative bacilli, accounting for 59% (10/17), followed by gram-positive cocci, accounting for 41% (7/17), results seen in Table 7.

### 4. Discussion

With diverse and nontypical manifestations in clinic, hematosepsis caused by suspicious or confirmed infectious SIRS in a

**Table 2**  
Comparison of sCD14-ST, PCT, CRP, and WBC between hematosepsis group and nonhematosepsis group (quartiles, mean, SD).


Group	Cases	sCD14-ST, ng/mL	PCT, $\mu$ g/L	CRP, mg/L	WBC, $10^9/L$
Hematosepsis group	42	786.04 (674.96–897.12) <sup>*,†,‡</sup>	11.62 $\pm$ 5.18	21.82 $\pm$ 20.81	12.60 $\pm$ 6.70
Nonhematosepsis group	54	626.00 (556.01–695.98) <sup>*</sup>	12.78 $\pm$ 7.91	18.76 $\pm$ 13.59	13.32 $\pm$ 5.48
Noninfectious group	44	207.86 (203.74–211.98)	—	—	—
Healthy control group	53	124.20 (113.73–134.68)	—	—	—
$\chi^2$		157.231	—	—	—
$P$		$< .01$	—	—	—

CRP = C reactive protein, PCT = procalcitonin, SD = standard deviation, sCD14-ST = soluble cluster of differentiation 14 subtype, WBC = leukocyte.

<sup>\*</sup> Compared with healthy control group,  $P < .01$ .

<sup>†</sup> Compared with nonhematosepsis group,  $P < .05$ .

<sup>‡</sup> Compared with noninfectious group,  $P < .01$ .



**Figure 3.** ROC curves of sCD14-ST, WBC, CRP, and PCT results in 42 neonates with hematosepsis.

special group on neonatal period, which imposes a serious threat to the lives of neonates. Therefore, it is urgent to find out a laboratory blood marker for fast and accurate diagnosis.<sup>[11]</sup>

As one of indexes of systemic inflammatory response, sCD14-ST level in whole blood plays an important role in the process of bacterial infection, particularly, it is closely related to the progress of hematosepsis associated with systemic multiple organ failure.<sup>[13]</sup> Our study shows that the sCD14-ST level in whole blood in hematosepsis group was obviously higher than those in nonhematosepsis group, noninfectious SIRS group, and healthy control group ( $P < .01$ ) suggesting that it could be an indicator for identifying hematosepsis and nonhematosepsis.

Resch et al conformed that PCT level is the most sensitive index for diagnosis of hematosepsis within 12 hours after birth and may be used for diagnosis of hematosepsis at the early stage. However, the diagnosis result based on fair increase of PCT level in the premature infant may be false negative.<sup>[14]</sup> The significant difference in sCD14-ST level ( $P < .05$ ) and no difference in the levels of PCT, CRP, and WBC ( $P > .05$ ) were found in our study before treatment between hematosepsis and nonhematosepsis group. It appeared that sCD14-ST has guiding significance to some extent in identifying hematosepsis from nonhematosepsis. Due to lack of anaerobic and fungal culture conditions, we collected the samples with such bacteria into nonhematosepsis group by mistake. Thus, the reliability of data should be verified by the culture of various bacteria and the research on a large quantity of samples collected from the neonates at different ages.

With the ROC curve analysis compared with sCD14-ST, PCT, CRP, and WBC. We found that the value of in diagnosis of sepsis,

sCD14-ST AUC is the largest, meanwhile the sensitivity is 95.2% and the specificity is 84.9%. It suggested that sCD14-ST has certain advantages in early and effective diagnosis of neonatal sepsis.

As one of the main receptors of LPS, sCD14-ST combines with the LPS in bacterial cell wall, particularly in SIRS caused by gram-negative bacteria infection.<sup>[12]</sup> Although blood culture has been recognized as the “gold standard” for diagnosis of hematosepsis, false positive or negative result may appear due to the effect of various external factors.<sup>[16,17]</sup> Some scholars have found that sCD14-ST level could help to identify the neonatal hematosepsis caused by gram-positive bacterial infection or gram-negative bacterial infection.<sup>[18]</sup> However, our study showed that there was no statistically significant difference in sCD14-ST levels between gram-positive bacterial group and gram-negative bacterial group in 42 cases of neonatal hematosepsis ( $P > .05$ ). Such inconsistency may be attributed to less samples, species specificity, hospital infection, etc. Therefore, we need to test a large quantity of samples to confirmed whether sCD14-ST level in whole blood can be used to identify the hematosepsis caused by gram-positive or gram-negative bacteria infection.

However, it has confirmed that sCD14-ST as a blood marker can be used for the research and judgment of severity of neonatal hematosepsis and the prognosis thereof.<sup>[19–21]</sup> Currently, sCD14-ST level has been reported as an index for diagnosis and evaluation of hematosepsis in the infant with a low birth weight.<sup>[22]</sup> As there are only a few infants with a low birth weight among the subjects of this study, the above-mentioned report is not supported and further research on a large quantity of samples collected from infants with different birth weights is yet to be conducted.

In our study, APACHE-II score was assigned to each neonate in hematosepsis group before treatment, and the correlation between APACHE-II score and sCD14-ST level was analyzed. The results showed that in hematosepsis group, sCD14-ST was positively correlated with APACHE-II score ( $R$ -value=0.415,  $P < .01$ ) and the sCD14-ST level, APACHE-II score, PCT, WBC, and CRP before and after treatment were decreased obviously ( $P < .01$ ), which is consistent with the findings that sCD14-ST level in the patient with hematosepsis markedly increased and such increase was correlated with the severity and prognosis of hematosepsis.<sup>[23]</sup> According to these findings, sCD14-ST level can be taken as an important laboratory index for early diagnosis of infectious diseases and evaluated the severity of neonatal hematosepsis with sCD14-ST level in combination with APACHE-II score.

Additionally, the constituent ratio of bacterial in 42 cases of neonatal hematosepsis demonstrated that gram-positive cocci comprised 60% (25/42) of infections, followed by gram-negative bacilli, accounting for 40% (17/42). The results showed that the

**Table 3**

**ROC curve analysis and evaluation of diagnostic capabilities of 4 indexes in 42 neonates with hematosepsis.**

Items	AUC <sup>ROC</sup>	Diagnosis of cut-off value	Sensitivity (%)	Specificity (%)	Youden index	SE	P	95% CI
sCD14-ST	0.942*	304.5	95.2*	84.9*	0.801	0.022	.000	0.900–0.986
PCT	0.876	7.44	88.1	81.1	0.692	0.040	.000	0.789–0.954
CRP	0.82	9.075	71.4	83	0.544	0.046	.000	0.731–0.910
WBC	0.752	8.4	73.8	83	0.568	0.055	.000	0.645–0.859

Note 1: SE represents standard error, P refers to the comparison of AUC with 0.5 (i.e., AUC of a diagnostic test without any diagnostic value); Note 2: compared with PCT, WBC, and CRP respectively. AUC=area under curve, CI=confidence interval, CRP=C reactive protein, PCT=procalcitonin, ROC=receiver operating characteristic curve, sCD14-ST=soluble cluster of differentiation 14 subtype, WBC=leukocyte.

\*  $P < .01$ .

**Table 4**

**Changes in sCD14-ST, PCT, WBC, CRP, and APACHE-II score of neonates with hematosepsis before and after treatment (quartiles, mean, SD).**

Treatment of days	N	sCD14-ST, ng/L	APACHE-II, score	PCT, $\mu\text{g/L}$	CRP, mg/L	WBC, $10^9/\text{L}$
Before the treatment	42	786.04 (674.96–897.12)	37.51 $\pm$ 13.69	11.62 $\pm$ 5.18	21.82 $\pm$ 20.81	12.60 $\pm$ 6.70
Treatment for 3 days	42	533.1 (451.05–615.13)	19.52 $\pm$ 6.41	4.26 $\pm$ 3.81	7.39 $\pm$ 8.16	11.9 $\pm$ 3.57
Treatment for 5 days	42	359.9 (292.91–426.89)	12.35 $\pm$ 3.39	3.23 $\pm$ 2.86	6.34 $\pm$ 4.19	9.18 $\pm$ 3.44
$\chi^2$		35.019	78.399	52.363	25.912	7.252
P		.000	.000	.000	.000	.027

APACHE = acute physiology and chronic health evaluation, CRP = C reactive protein, PCT = procalcitonin, sCD14-ST = soluble cluster of differentiation 14 subtype, SD = standard deviation, WBC = leukocyte.

**Table 5**

**Comparison of sCD14-ST between G<sup>+</sup> bacteria group and G<sup>-</sup> bacteria group in 42 neonates with hematosepsis (quartiles, mean, SD).**

Group	Cases	sCD14-ST, ng/L
Gram-positive group	25	802.92 (669.55–936.28)*,†
Gram-negative group	17	761.24 (550.54–971.92)*
Healthy control group	53	124.20 (113.73–134.68)
$\chi^2$		69.065
P		.00

sCD14-ST = soluble cluster of differentiation 14 subtype, SD = standard deviation.

\* Compared with healthy control group,  $P < .01$ .

† Compared with G<sup>-</sup> bacteria group,  $P > .05$ .

**Table 6**

**Distribution and constituent ratio of pathogenic bacteria in 42 neonates with hematosepsis (n = 42).**

Pathogenic bacteria	Cases	Constituent ratio (%)
Gram-positive cocci	25	60.0
<i>Staphylococcus epidermidis</i>	6	14.3
<i>Staphylococcus aureus</i>	6	14.3
<i>Streptococcus agalactiae</i>	4	9.5
<i>Staphylococcus haemolyticus</i>	3	7.1
Type II <i>Streptococcus bovis</i>	2	4.8
<i>Staphylococcus saprophyticus</i>	1	2.5
<i>Streptococcus pneumoniae</i>	1	2.5
Other streptococcus	1	2.5
<i>Enterococcus faecium</i>	1	2.5
Gram-negative bacillus	17	40.0
<i>Escherichia coli</i>	12	28.1
<i>Salmonella dublin</i>	2	4.8
<i>Serratia marcescens</i>	3	7.1

**Table 7**

**Distribution and constituent ratio of pathogenic bacteria in premature infants of hematosepsis group (n = 17).**

Pathogenic bacteria	Cases	Constituent ratio (%)
Gram-positive cocci	7	41.0
<i>Staphylococcus epidermidis</i>	6	35.0
<i>Streptococcus pneumoniae</i>	1	6.0
Gram-negative bacillus	10	59.0
<i>Escherichia coli</i>	5	29.0
<i>Salmonella dublin</i>	2	12.0
<i>Serratia marcescens</i>	3	18.0

neonate with hematosepsis was mainly infected with gram-positive bacteria (*Staphylococcus*), among which *Staphylococcus aureus* and *Streptococcus agalactiae* were clinically significant and other staphylococci such as *Staphylococcus epidermidis* and *Staphylococcus saprophyticus* were considered as contaminants, and then with gram-negative bacteria (predominantly *Escherichia coli*). The results are consistent with the findings of Srinivasa and Arunkumar that *S aureus* as gram-positive bacteria were the main factor leading to neonatal hematosepsis,<sup>[24]</sup> and with the reports that different pathogenic bacteria of neonatal hematosepsis vary in distribution.<sup>[20,21]</sup> The research of Stoll et al<sup>[13]</sup> mentioned that approximately 73% of patients infected with streptococcus were term infants, which is almost consistent with the result of this study. However, we found no streptococcus other than *S agalactiae*, which may be related to species difference or the limited quantity of samples. We found the bacteria in the premature infant with hematosepsis were mainly gram-negative bacteria (bacilli), accounting for 59% (10/17), followed by gram-positive bacteria (cocci), accounting for 41% (7/17), which is consistent with the findings of the scholars that the hematosepsis in the premature infant was mainly caused by gram-negative bacteria infection<sup>[25,26]</sup>; and such infection was dominated by *E coli*, which is also consistent with the description of Stoll et al<sup>[13]</sup> that about 81% of patients infected with *E coli* were premature infants. Since premature infants are more susceptible to hematosepsis due to immature tissues and organs, low birth weight, staying in ICU for a long period of time, blue-light irradiation, subcutaneous catheter indwelling, central venous catheterization and mechanical ventilation, the blood culture result of premature infants is considered to be related to hospital infection.<sup>[27,28]</sup>

Not all of bacteria caused hematosepsis can be detected by traditional blood culture because of maternal's own factor and the difference in microbial species.<sup>[29]</sup> Biedenbach et al<sup>[30]</sup> found that neonatal hematosepsis caused by *Klebsiella pneumoniae* and *Pseudomonas aeruginosa* was attributed to overuse of antibiotic. But our study did not find any of the above 2 bacteria, which may be related to the living environment and hospital infection of mother and child; meanwhile, considering limited number of samples studied, the research and analysis of a large quantity of samples is yet to be done.

## 5. Conclusion

Compared with the conventional laboratory indexes, the determination of sCD14-ST in whole blood can be used for early diagnosis of hematosepsis and nonhematosepsis in neonates. It is worthy of clinical application and promotion in monitoring the therapeutic effect of hematosepsis and evaluating the severity with APACHE-II.

## References

- [1] Weston EJ, Pondo T, Lewis MM, et al. The burden of invasive early-onset neonatal sepsis in the United States, 2005–2008. *Pediatr Infect Dis J* 2011;30:937–41.
- [2] Chiabi A, Djoupomb M, Mall E, et al. The clinical and bacteriological spectrum of neonatal sepsis in a tertiary hospital in Yaounde, Cameroon. *Iran J Pediatr* 2011;21:441–8.
- [3] Aly H, Herson V, Duncan A, et al. Is bloodstream infection preventable among premature infants. A tale of two cities. *Pediatrics* 2005;115:1513–8.
- [4] Cimiotti JP, Haas J, Saiman L, et al. Impact of staffing on bloodstream infections in the neonatal intensive care unit. *Arch Pediatr Adolesc Med* 2006;160:832–6.
- [5] Liu T, Chen HW, Liang DY, et al. Progress of prognostic markers in sepsis. *Int J Lab Med* 2014;35:2794–6.
- [6] Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. *Pediatr Crit Care Med* 2005;6:2–8.
- [7] Knaus WA, Draper EA, Wagner DP, et al. APACHE II: a severity of disease classification system. *Crit Care Med* 1985;13:818–29.
- [8] Jing-jing S, Yong-qiang W, Cao S, et al. Serum PCT, CRP and the dynamic change of APACHE II score in the prediction of polytrauma to incorporate the value in the prognosis of patients with sepsis. *J Emerg Med China* 2011;31:983–6.
- [9] Kweon OJ, Choi JH, Park SK, Park AJ. Usefulness of presepsin (sCD14 subtype) measurements as a new marker for the diagnosis and prediction of disease severity of sepsis in the Korean population. *J Crit Care* 2014;29:965–70.
- [10] Yu H. *Diagnosis of Medical Statistics*. People's Medical Publishing House, Beijing;2005;22–30.
- [11] Carvalho PRA, Feldens L, Seitz EE, et al. Prevalence of systemic inflammatory syndromes at a tertiary pediatric intensive care unit. *J Pediatr (Rio J)* 2005;81:143–8.
- [12] Masson S, Caironi P, Fanizza C, et al. Circulating presepsin (soluble CD14 subtype) as a marker of host response in patients with severe sepsis or septic shock: data from the multicenter, randomized ALBIOS trial. *Intensive Care Med* 2015;41:12–20.
- [13] Stoll BJ, Hansen NI, Sanchez PJ, et al. Early onset neonatal sepsis: the burden of group B *Streptococcal* and *E. coli* disease continues. *Pediatrics* 2011;127:817–26.
- [14] Resch B, Gusenleitner W, Muller WD. Procalcitonin and interleukin-6 in the diagnosis of early-onset sepsis of the neonate. *Acta Paediatr* 2003;92:243–5.
- [15] Gluck T, Silver J, Epstein M, et al. Parameters influencing membrane CD14 expression and soluble CD14 levels in sepsis. *Eur J Med Res* 2001;6:351–8.
- [16] Tarai B, Das P, Kumar D, et al. Comparative evaluation of paired blood culture (aerobic/aerobic) and single blood culture, along with clinical importance in catheter versus peripheral line at a tertiary care hospital. *Indian J Med Microbiol* 2012;30:187–92.
- [17] Chen X, Chun-ming J. The research progress of neonatal sepsis diagnosis index. *Int J Pediatr* 2013;40:148–51.
- [18] Mussap M, Noto A, Fravega M, Fanos V. Soluble CD14 subtype presepsin (sCD14-ST) and lipopolysaccharide binding protein (LBP) in neonatal sepsis: new clinical and analytical perspectives for two old biomarkers. *J Matern Fetal Neonatal Med* 2011;24(Suppl 2):12–4.
- [19] Kweon OJ, Choi JH, Park SK, et al. Usefulness of presepsin (sCD14 subtype) measurements as a new marker for the diagnosis and prediction of disease severity of sepsis in the Korean population. *J Crit Care* 2014;29:965–70.
- [20] Behnes M, Bertsch T, Lepiorz D, et al. Diagnostic and prognostic utility of soluble CD 14 subtype (presepsin) for severe sepsis and septic shock during the first week of intensive care treatment. *Crit Care* 2014;18:507.
- [21] Liu B, Yin Q, Chen YX, et al. Role of presepsin (sCD14-ST) and the CURB65 scoring system in predicting severity and outcome of community-acquired pneumonia in an emergency department. *Respir Med* 2014;108:1204–13.
- [22] Leante-Castellanos JL, de Guadiana-Romualdo LG, Fuentes-Gutiérrez C. The value of lipopolysaccharide binding protein for diagnosis of late-onset neonatal sepsis in very low birth weight infants. *J Perinat Med* 2015;43:253–7.
- [23] Meisner M. *Procalcitonin—Biochemistry and Clinical Diagnosis*. 2010; UNI-MED, Bremen:ISBN 978-3-8374-1241-3.
- [24] Srinivasa S, Arunkumar D. Bacterial isolates and their Antibiotic susceptibility patterns in Neonatal sepsis. *Curr Pediatr Res* 2014;18:83–6.
- [25] Mussap M, Puxeddu E, Puddu M, et al. Soluble CD14 subtype (sCD14-ST) presepsin in premature and full term critically ill newborns with sepsis and SIRS. *Clin Chim Acta* 2015;451:65–70.
- [26] Aalto H, Takala A, Kautiainen H, et al. Monocyte CD14 and soluble CD14 in predicting mortality of patients with severe community acquired infection. *Scand J Infect Dis* 2007;39:596–603.
- [27] Kaufman D, Fairchild KD. Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants. *Clin Microbiol Rev* 2004;17:638–80.
- [28] Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. *Pediatrics* 2002;110(2 part 1):285–91.
- [29] Kiwanuka J, Bazira J, Mwangi J, et al. The microbial spectrum of neonatal sepsis in Uganda: recovery of culturable bacteria in mother-infant pairs. *PLoS ONE* 2013;8:e72775.
- [30] Biedenbach DJ, Moet GJ, Jones RN. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997–2002). *Diagn Microbiol Infect Dis* 2004;50:59–69.